For the year ending 2025-12-31, TERN has $1,025,078K in assets. $18,554K in debts. $524,747K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 524,747 | 161,439 | 79,926 | 143,235 |
| Marketable securities | 494,235 | 196,725 | 183,514 | 139,879 |
| Prepaid expenses and other current assets | 5,212 | 3,945 | 3,992 | 2,071 |
| Total current assets | 1,024,194 | 362,109 | 267,432 | 285,185 |
| Property and equipment, gross | 729 | 2,114 | 2,115 | 2,159 |
| Less accumulated depreciation | 682 | 1,892 | 1,609 | 1,402 |
| Property and equipment, net | 47 | 222 | 506 | 757 |
| Operating lease assets | 837 | 1,248 | 523 | 1,047 |
| Other assets | 0 | 350 | 56 | 37 |
| Total assets | 1,025,078 | 363,929 | 268,517 | 287,026 |
| Accounts payable | 1,721 | 2,148 | 2,515 | 1,645 |
| Accrued expenses and other current liabilities | 14,216 | 13,074 | 8,826 | 6,162 |
| Current portion of operating lease liabilities | 474 | 428 | 603 | 661 |
| Total current liabilities | 16,411 | 15,650 | 11,944 | 8,468 |
| Deferred rent, net of current portion | - | - | - | 0 |
| Taxes payable, non-current | 1,698 | 1,490 | 1,206 | 1,071 |
| Operating lease liabilities, non-current | 445 | 919 | 0 | 544 |
| Total liabilities | 18,554 | 18,059 | 13,150 | 10,083 |
| Common stock, 0.0001 par value, 150,000,000 shares authorized at december 31, 2025 and 2024 112,324,683 and 87,126,583 shares issued and outstanding at december 31, 2025 and 2024, respectively | 11 | 9 | 6 | 5 |
| Additional paid-in capital | 1,523,941 | 767,621 | 588,008 | 520,178 |
| Accumulated other comprehensive loss | 260 | -279 | -19 | -822 |
| Accumulated deficit | -517,688 | -421,481 | -332,628 | -242,418 |
| Total stockholders' equity | 1,006,524 | 345,870 | 255,367 | 276,943 |
| Total liabilities and stockholders' equity | 1,025,078 | 363,929 | 268,517 | 287,026 |
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)